Ovarian cancer susceptibility alleles and risk of ovarian cancer in BRCA1 and BRCA2 mutation carriers

被引:34
|
作者
Ramus, Susan J. [2 ]
Antoniou, Antonis C. [1 ]
Kuchenbaecker, Karoline B.
Soucy, Penny [3 ,4 ]
Beesley, Jonathan [5 ]
Chen, Xiaoqing [5 ]
McGuffog, Lesley
Sinilnikova, Olga M. [6 ,7 ]
Healey, Sue [5 ]
Barrowdale, Daniel
Lee, Andrew
Thomassen, Mads [8 ]
机构
[1] Univ Cambridge, Ctr Canc Genet Epidemiol, Dept Publ Hlth & Primary Care, Strangeways Res Lab, Cambridge CB1 8RN, England
[2] Univ So Calif, Keck Sch Med, Dept Prevent Med, Los Angeles, CA 90033 USA
[3] Univ Laval, Quebec City, PQ, Canada
[4] Ctr Hosp Univ Quebec, Canc Genom Lab, Quebec City, PQ, Canada
[5] Queensland Inst Med Res, Genet & Populat Hlth Div, Herston, Qld 4006, Australia
[6] Ctr Hosp Univ Lyon, Ctr Leon Berard, Unite Mixte Genet Constitut Canc Frequents, Lyon, France
[7] Univ Lyon 1, INSERM, CNRS, Ctr Rech Cancerol Lyon,U1052,UMR5286, F-69365 Lyon, France
[8] Odense Univ Hosp, Dept Clin Genet, DK-5000 Odense, Denmark
基金
美国国家卫生研究院; 加拿大健康研究院; 芬兰科学院; 俄罗斯基础研究基金会; 澳大利亚国家健康与医学研究理事会; 英国医学研究理事会;
关键词
ovarian cancer; BRCA1; BRCA2; association; SNP; GENOME-WIDE ASSOCIATION; BREAST-CANCER; POPULATION; LOCUS; 8Q24; POSITION; 9P22.2; 1P11.2;
D O I
10.1002/humu.22025
中图分类号
Q3 [遗传学];
学科分类号
071007 ; 090102 ;
摘要
Germline mutations in BRCA1 and BRCA2 are associated with increased risks of breast and ovarian cancer. A genome-wide association study (GWAS) identified six alleles associated with risk of ovarian cancer for women in the general population. We evaluated four of these loci as potential modifiers of ovarian cancer risk for BRCA1 and BRCA2 mutation carriers. Four single-nucleotide polymorphisms (SNPs), rs10088218 (at 8q24), rs2665390 (at 3q25), rs717852 (at 2q31), and rs9303542 (at 17q21), were genotyped in 12,599 BRCA1 and 7,132 BRCA2 carriers, including 2,678 ovarian cancer cases. Associations were evaluated within a retrospective cohort approach. All four loci were associated with ovarian cancer risk in BRCA2 carriers; rs10088218 per-allele hazard ratio (HR) = 0.81 (95% CI: 0.670.98) P-trend = 0.033, rs2665390 HR = 1.48 (95% CI: 1.211.83) P-trend = 1.8 x 10-4, rs717852 HR = 1.25 (95% CI: 1.101.42) P-trend = 6.6 x 10-4, rs9303542 HR = 1.16 (95% CI: 1.021.33) P-trend = 0.026. Two loci were associated with ovarian cancer risk in BRCA1 carriers; rs10088218 per-allele HR = 0.89 (95% CI: 0.810.99) P-trend = 0.029, rs2665390 HR = 1.25 (95% CI: 1.101.42) P-trend = 6.1 x 10-4. The HR estimates for the remaining loci were consistent with odds ratio estimates for the general population. The identification of multiple loci modifying ovarian cancer risk may be useful for counseling women with BRCA1 and BRCA2 mutations regarding their risk of ovarian cancer. Hum Mutat 33:690702, 2012. (c) 2012 Wiley Periodicals, Inc.
引用
收藏
页码:690 / 702
页数:13
相关论文
共 50 条
  • [31] Reproductive factors and ovarian cancer risk in Jewish BRCA1 and BRCA2 mutation carriers (United States)
    Francesmary Modugno
    Roxana Moslehi
    Roberta B. Ness
    Deborah Brooks Nelson
    Steven Belle
    Jeffrey A. Kant
    James E. Wheeler
    Aimee Wonderlick
    David Fishman
    Beth Karlan
    Harvey Risch
    Daniel W. Cramer
    Marie-Pierre Dube
    Steven A. Narod
    Cancer Causes & Control, 2003, 14 : 439 - 446
  • [32] Parity, oral contraceptives, and the risk of ovarian cancer among carriers and noncarriers of a BRCA1 or BRCA2 mutation
    Modan, B
    Hartge, P
    Hirsh-Yechezkel, G
    Chetrit, A
    Lubin, F
    Beller, U
    Ben-Baruch, G
    Fishman, A
    Menczer, J
    Struewing, JP
    Tucker, MA
    Wacholder, S
    Ebbers, SM
    Friedman, E
    Piura, B
    NEW ENGLAND JOURNAL OF MEDICINE, 2001, 345 (04): : 235 - 240
  • [33] Risk of uterine cancer for BRCA1 and BRCA2 mutation carriers
    Lee, Y. C.
    Milne, R. L.
    Lheureux, S.
    Friedlander, M.
    McLachlan, S. A.
    Martin, K. L.
    Bernardini, M. Q.
    Smith, C.
    Picken, S.
    Nesci, S.
    Hopper, J. L.
    Phillips, K. A.
    EUROPEAN JOURNAL OF CANCER, 2017, 84 : 114 - 120
  • [34] Evaluation of Polygenic Risk Scores for Breast and Ovarian Cancer Risk Prediction in BRCA1 and BRCA2 Mutation Carriers
    Kuchenbaecker, Karoline B.
    McGuffog, Lesley
    Barrowdale, Daniel
    Lee, Andrew
    Soucy, Penny
    Dennis, Joe
    Domchek, Susan M.
    Robson, Mark
    Spurdle, Amanda B.
    Ramus, Susan J.
    Mavaddat, Nasim
    Terry, Mary Beth
    Neuhausen, Susan L.
    Schmutzler, Rita Katharina
    Simard, Jacques
    Pharoah, Paul D. P.
    Offit, Kenneth
    Couch, Fergus J.
    Chenevix-Trench, Georgia
    Easton, Douglas F.
    Antoniou, Antonis C.
    JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2017, 109 (07):
  • [35] Tamoxifen and the risk of ovarian cancer in BRCA1 mutation carriers
    Vicus, Danielle
    Rosen, Barry
    Lubinski, Jan
    Domchek, Susan
    Kauff, Noah D.
    Lynch, Henry T.
    Isaacs, Claudine
    Tung, Nadine
    Sun, Ping
    Narod, Steven A.
    GYNECOLOGIC ONCOLOGY, 2009, 115 (01) : 135 - 137
  • [36] The Contribution of BRCA1 and BRCA2 to Ovarian Cancer
    Ramus, Susan J.
    Gayther, Simon A.
    MOLECULAR ONCOLOGY, 2009, 3 (02) : 138 - 150
  • [37] Inactivation of BRCA1 and BRCA2 in ovarian cancer
    Hilton, JL
    Geisler, JP
    Rathe, JA
    Hattermann-Zogg, MA
    DeYoung, B
    Buller, RE
    JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2002, 94 (18): : 1396 - 1406
  • [38] BRCA1 and BRCA2 Mutations in Ovarian Cancer
    Buerkle, Bernd
    Tempfer, Clemens
    JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2012, 307 (04): : 359 - 359
  • [39] The risk of primary and contralateral breast cancer after ovarian cancer in BRCA1/BRCA2 mutation carriers Implications for Counseling
    Vencken, Peggy M. L. H.
    Kriege, Mieke
    Hooning, Maartje
    Menke-Pluymers, Marian B.
    Heemskerk-Gerritsen, Bernadette A. M.
    van Doorn, Lena C.
    Collee, Margriet M.
    Jager, Agnes
    van Montfort, Cees
    Burger, Curt W.
    Seynaeve, Caroline
    CANCER, 2013, 119 (05) : 955 - 962
  • [40] Polymorphisms in BRCA1 and BRCA2 and risk of epithelial ovarian cancer
    Wenham, RM
    Schildkraut, JM
    McLean, K
    Calingaert, B
    Bentley, RC
    Marks, J
    Berchuck, A
    CLINICAL CANCER RESEARCH, 2003, 9 (12) : 4396 - 4403